Results 171 to 180 of about 21,014 (260)

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Prenatal Syphilis Screening Mandates and Maternal Syphilis Case Detection.

JAMA Health Forum
Baum SE, Agha L, Menzies NA, Cohen J.
europepmc   +1 more source

Preparing for the next pandemic: Reflections and recommendations from Florida. [PDF]

PLoS One
Liu A, Waldman RN, Deal B, Duff J, Batycki JN, Pretto EA, Saavedra J, Szapocznik J.   +7 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Corporate political activity of the food industry in the development of food policies in Latin America and the Caribbean: a narrative review of the current literature. [PDF]

Global Health
Lara-Mejía V, Villalobos-Pérez A, Tolentino-Mayo L, Théodore FL, Ayvar-Gama Y, Barquera S.   +5 more
europepmc   +1 more source

Community pharmacists' practices and perspectives on deprescribing high‐risk psychotropic medicines: National survey findings

British Journal of Clinical Pharmacology, EarlyView.
Aim To explore the practices, confidence and perspectives of community pharmacists in deprescribing high‐risk psychotropic medicines, including opioid analgesics, benzodiazepine, gabapentinoids and medicinal cannabis. Methods An anonymous, cross‐sectional national online survey was conducted between January and April 2025 among Australian community ...
Monica Jung, Louisa Picco, Aili V. Langford, Rose Laing, Jana Dostal, Suzanne Nielsen   +5 more
wiley   +1 more source

Hong Kong anti-human trafficking framework: what lessons can be learned from Europe? [PDF]

Front Sociol
Lo NP.
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

The Dynamics of Electoral Manipulation and Institutional Trust in Democracies: Election Timing, Blatant Fraud, and the Legitimacy of Governance. [PDF]

Public Opin Q
Higashijima M, Kadoya H, Yanai Y.
europepmc   +1 more source